Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here.
PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape
Recent Articles
AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma
In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420, the agent continued to demonstrate clinical activity in patients...
July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9
This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.
Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis
In late 2018, the U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children with blastic plasmacytoid dendritic cell neoplasm,...
Luteinizing Hormone Suppression Improves Post-Chemotherapy Hematopoietic Recovery in Patients With Leukemia
Treatment of leukemia with intensive chemotherapy increases patients’ risk of infection and bleeding due to myelosuppression, but according to results from a study presented...
Bispecific Antibody REGN1979 Shows Promising Efficacy in Relapsed/Refractory Non-Hodgkin Lymphomas
In a small phase I study of patients with relapsed/refractory non-Hodgkin lymphoma (NHL), approximately half of patients responded to treatment with REGN1979, an anti-CD20...
Current Issue
July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9
This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.
